The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus

Laura K. McMullan, Mike Flint, Julie Dyall, César Albariño, Gene G. Olinger, Scott Foster, Phiroze Sethna, Lisa E. Hensley, Stuart T. Nichol, E. Randall Lanier, Christina F. Spiropoulou

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Brincidofovir (BCV) is the 3-hexadecyloxy-1-propanol (HDP) lipid conjugate of the acyclic nucleoside phosphonate cidofovir (CDV). BCV has established broad-spectrum activity against double-stranded DNA (dsDNA) viruses; however, its activity against RNA viruses has been less thoroughly evaluated. Here, we report that BCV inhibited infection of Ebola virus in multiple human cell lines. Unlike the mechanism of action for BCV against cytomegalovirus and other dsDNA viruses, phosphorylation of CDV to the diphosphate form appeared unnecessary. Instead, antiviral activity required the lipid moiety and in vitro activity against EBOV was observed for several HDP-nucleotide conjugates.

Original languageEnglish (US)
Pages (from-to)71-78
Number of pages8
JournalAntiviral research
Volume125
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • Antiviral therapy
  • Brincidofovir
  • Ebola
  • In vitro screen

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint

Dive into the research topics of 'The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus'. Together they form a unique fingerprint.

Cite this